Protective hematopoietic effect of estrogens in a mouse model of thrombosis

Respective roles of nuclear versus membrane estrogen receptor α

Marie Cécile Valera, Coralie Fontaine, Françoise Lenfant, Cendrine Cabou, Maeva Guillaume, Natalia Smirnova, Sung Hoon Kim, Pierre Chambon, John A. Katzenellenbogen, Benita S Katzenellenbogen, Bernard Payrastre, Jean François Arnal

Research output: Contribution to journalArticle

Abstract

We recently reported that chronic 17β-estradiol (E2) treatment in mice decreases platelet responsiveness, prolongs the tail-bleeding time and protects against acute thromboembolism via the hematopoietic estrogen receptor alpha (ERα), and independently of ERβ. Here, we have explored the respective roles of membrane vs nuclear actions of ERαin this process, using: 1) the selective activator of membrane ERα: estrogen dendrimer conjugate, and 2) mouse models with mutations in ERα. The selective targeting of activation function 2 of ERα provides a model of nuclear ERα loss-of-function, whereas mutation of the ERαpalmitoylation site leads to a model of membrane ERα deficiency. The combination of pharmacological and genetic approaches including hematopoietic chimera mice demonstrated that absence of either membrane or nuclear ERαactivation in bone marrow does not prevent the prolongation of the tail-bleeding time, suggesting a redundancy of thesetwofunctions for this E2 effect. In addition, although hematopoieticmembraneERα is neither sufficient nor necessary to protect E2-treated mice from collagen/epinephrine-induced thromboembolism, the protection against death-induced thromboembolism is significantly reduced in the absence of hematopoietic nuclear ERαactivation. Overall, this study emphasizes that hematopoietic cells (likely megakaryocytes and possibly immune cells) constitute an important target in the antithrombotic effects of estrogens, and delineate for the first time in vivo the respective roles of membrane vs nuclear ERα effects, with a prominent role of the latter.

Original languageEnglish (US)
Pages (from-to)4293-4301
Number of pages9
JournalEndocrinology
Volume156
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Estrogen Receptor alpha
Nuclear Envelope
Estrogen Receptors
Estrogens
Thrombosis
Thromboembolism
Bleeding Time
Tail
Dendrimers
Mutation
Megakaryocytes
Membranes
Epinephrine
Estradiol
Collagen
Blood Platelets
Bone Marrow
Pharmacology

ASJC Scopus subject areas

  • Endocrinology

Cite this

Valera, M. C., Fontaine, C., Lenfant, F., Cabou, C., Guillaume, M., Smirnova, N., ... Arnal, J. F. (2015). Protective hematopoietic effect of estrogens in a mouse model of thrombosis: Respective roles of nuclear versus membrane estrogen receptor α. Endocrinology, 156(11), 4293-4301. https://doi.org/10.1210/en.2015-1522

Protective hematopoietic effect of estrogens in a mouse model of thrombosis : Respective roles of nuclear versus membrane estrogen receptor α. / Valera, Marie Cécile; Fontaine, Coralie; Lenfant, Françoise; Cabou, Cendrine; Guillaume, Maeva; Smirnova, Natalia; Kim, Sung Hoon; Chambon, Pierre; Katzenellenbogen, John A.; Katzenellenbogen, Benita S; Payrastre, Bernard; Arnal, Jean François.

In: Endocrinology, Vol. 156, No. 11, 01.11.2015, p. 4293-4301.

Research output: Contribution to journalArticle

Valera, MC, Fontaine, C, Lenfant, F, Cabou, C, Guillaume, M, Smirnova, N, Kim, SH, Chambon, P, Katzenellenbogen, JA, Katzenellenbogen, BS, Payrastre, B & Arnal, JF 2015, 'Protective hematopoietic effect of estrogens in a mouse model of thrombosis: Respective roles of nuclear versus membrane estrogen receptor α', Endocrinology, vol. 156, no. 11, pp. 4293-4301. https://doi.org/10.1210/en.2015-1522
Valera, Marie Cécile ; Fontaine, Coralie ; Lenfant, Françoise ; Cabou, Cendrine ; Guillaume, Maeva ; Smirnova, Natalia ; Kim, Sung Hoon ; Chambon, Pierre ; Katzenellenbogen, John A. ; Katzenellenbogen, Benita S ; Payrastre, Bernard ; Arnal, Jean François. / Protective hematopoietic effect of estrogens in a mouse model of thrombosis : Respective roles of nuclear versus membrane estrogen receptor α. In: Endocrinology. 2015 ; Vol. 156, No. 11. pp. 4293-4301.
@article{5aa34fdb771d46e6acc06e33d00812ec,
title = "Protective hematopoietic effect of estrogens in a mouse model of thrombosis: Respective roles of nuclear versus membrane estrogen receptor α",
abstract = "We recently reported that chronic 17β-estradiol (E2) treatment in mice decreases platelet responsiveness, prolongs the tail-bleeding time and protects against acute thromboembolism via the hematopoietic estrogen receptor alpha (ERα), and independently of ERβ. Here, we have explored the respective roles of membrane vs nuclear actions of ERαin this process, using: 1) the selective activator of membrane ERα: estrogen dendrimer conjugate, and 2) mouse models with mutations in ERα. The selective targeting of activation function 2 of ERα provides a model of nuclear ERα loss-of-function, whereas mutation of the ERαpalmitoylation site leads to a model of membrane ERα deficiency. The combination of pharmacological and genetic approaches including hematopoietic chimera mice demonstrated that absence of either membrane or nuclear ERαactivation in bone marrow does not prevent the prolongation of the tail-bleeding time, suggesting a redundancy of thesetwofunctions for this E2 effect. In addition, although hematopoieticmembraneERα is neither sufficient nor necessary to protect E2-treated mice from collagen/epinephrine-induced thromboembolism, the protection against death-induced thromboembolism is significantly reduced in the absence of hematopoietic nuclear ERαactivation. Overall, this study emphasizes that hematopoietic cells (likely megakaryocytes and possibly immune cells) constitute an important target in the antithrombotic effects of estrogens, and delineate for the first time in vivo the respective roles of membrane vs nuclear ERα effects, with a prominent role of the latter.",
author = "Valera, {Marie C{\'e}cile} and Coralie Fontaine and Fran{\cc}oise Lenfant and Cendrine Cabou and Maeva Guillaume and Natalia Smirnova and Kim, {Sung Hoon} and Pierre Chambon and Katzenellenbogen, {John A.} and Katzenellenbogen, {Benita S} and Bernard Payrastre and Arnal, {Jean Fran{\cc}ois}",
year = "2015",
month = "11",
day = "1",
doi = "10.1210/en.2015-1522",
language = "English (US)",
volume = "156",
pages = "4293--4301",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - Protective hematopoietic effect of estrogens in a mouse model of thrombosis

T2 - Respective roles of nuclear versus membrane estrogen receptor α

AU - Valera, Marie Cécile

AU - Fontaine, Coralie

AU - Lenfant, Françoise

AU - Cabou, Cendrine

AU - Guillaume, Maeva

AU - Smirnova, Natalia

AU - Kim, Sung Hoon

AU - Chambon, Pierre

AU - Katzenellenbogen, John A.

AU - Katzenellenbogen, Benita S

AU - Payrastre, Bernard

AU - Arnal, Jean François

PY - 2015/11/1

Y1 - 2015/11/1

N2 - We recently reported that chronic 17β-estradiol (E2) treatment in mice decreases platelet responsiveness, prolongs the tail-bleeding time and protects against acute thromboembolism via the hematopoietic estrogen receptor alpha (ERα), and independently of ERβ. Here, we have explored the respective roles of membrane vs nuclear actions of ERαin this process, using: 1) the selective activator of membrane ERα: estrogen dendrimer conjugate, and 2) mouse models with mutations in ERα. The selective targeting of activation function 2 of ERα provides a model of nuclear ERα loss-of-function, whereas mutation of the ERαpalmitoylation site leads to a model of membrane ERα deficiency. The combination of pharmacological and genetic approaches including hematopoietic chimera mice demonstrated that absence of either membrane or nuclear ERαactivation in bone marrow does not prevent the prolongation of the tail-bleeding time, suggesting a redundancy of thesetwofunctions for this E2 effect. In addition, although hematopoieticmembraneERα is neither sufficient nor necessary to protect E2-treated mice from collagen/epinephrine-induced thromboembolism, the protection against death-induced thromboembolism is significantly reduced in the absence of hematopoietic nuclear ERαactivation. Overall, this study emphasizes that hematopoietic cells (likely megakaryocytes and possibly immune cells) constitute an important target in the antithrombotic effects of estrogens, and delineate for the first time in vivo the respective roles of membrane vs nuclear ERα effects, with a prominent role of the latter.

AB - We recently reported that chronic 17β-estradiol (E2) treatment in mice decreases platelet responsiveness, prolongs the tail-bleeding time and protects against acute thromboembolism via the hematopoietic estrogen receptor alpha (ERα), and independently of ERβ. Here, we have explored the respective roles of membrane vs nuclear actions of ERαin this process, using: 1) the selective activator of membrane ERα: estrogen dendrimer conjugate, and 2) mouse models with mutations in ERα. The selective targeting of activation function 2 of ERα provides a model of nuclear ERα loss-of-function, whereas mutation of the ERαpalmitoylation site leads to a model of membrane ERα deficiency. The combination of pharmacological and genetic approaches including hematopoietic chimera mice demonstrated that absence of either membrane or nuclear ERαactivation in bone marrow does not prevent the prolongation of the tail-bleeding time, suggesting a redundancy of thesetwofunctions for this E2 effect. In addition, although hematopoieticmembraneERα is neither sufficient nor necessary to protect E2-treated mice from collagen/epinephrine-induced thromboembolism, the protection against death-induced thromboembolism is significantly reduced in the absence of hematopoietic nuclear ERαactivation. Overall, this study emphasizes that hematopoietic cells (likely megakaryocytes and possibly immune cells) constitute an important target in the antithrombotic effects of estrogens, and delineate for the first time in vivo the respective roles of membrane vs nuclear ERα effects, with a prominent role of the latter.

UR - http://www.scopus.com/inward/record.url?scp=84946082896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946082896&partnerID=8YFLogxK

U2 - 10.1210/en.2015-1522

DO - 10.1210/en.2015-1522

M3 - Article

VL - 156

SP - 4293

EP - 4301

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 11

ER -